Korneev I A
Vopr Onkol. 2005;51(2):211-5.
The investigation deals with Ki-67 immunoreactivity assay in upper urinary tract transitional cell carcinoma (TCC) with respect to grade, stage and survival after radical surgery. In a retrospective study (5yrs) of 37 patients with TCC of the renal pelvis and ureter, who had undergone radical nephroureterectomy and bladder resection, pT1-pT4 lesions and G1-G3 tumors were identified. Ki-67 expression was evaluated by immunohistological staining (1:100; MIB-1; Immunotech. Inc., Westbrook, USA). By using fifteen x600 visual fields, Ki-67 labeling index (number of positive cells per 100 tumor cells) was found (mean +SD--29.7 +/- 9.22). There was a correlation between the index and tumor stage (p < 0.001) and grade (p = 0.002). The Ki-67 values in excess of 27 corresponded to high risk of bladder recurrence (p < 0.001) and short duration of recurrence development (p = 0.067) whereas, for the index of under 22, five-year progression-free survival was more frequent (p < 0.001). Having been tested in that study, discriminative modeling yielded the following parameters: sensitivity and specificity for bladder recurrence was 93% and 79% while for 5-year progression-free survival- 89% and 100%.
该研究探讨了上尿路移行细胞癌(TCC)中Ki-67免疫反应性检测与根治性手术后分级、分期及生存率的关系。在一项对37例肾盂和输尿管TCC患者进行的回顾性研究(5年)中,这些患者均接受了根治性肾输尿管切除术和膀胱切除术,确定了pT1 - pT4病变及G1 - G3肿瘤。通过免疫组织化学染色(1:100;MIB-1;美国韦斯特布鲁克免疫技术公司)评估Ki-67表达。使用15个×600视野,得出Ki-67标记指数(每100个肿瘤细胞中的阳性细胞数)(平均值±标准差 - 29.7±9.22)。该指数与肿瘤分期(p < 0.001)和分级(p = 0.002)之间存在相关性。Ki-67值超过27对应膀胱复发的高风险(p < 0.001)和复发发展的短持续时间(p = 0.067),而对于指数低于22的情况,五年无进展生存率更高(p < 0.001)。在该研究中进行测试后,判别模型得出以下参数:膀胱复发的敏感性和特异性分别为93%和79%,而五年无进展生存率的敏感性和特异性分别为89%和100%。